Terms: = Ovarian cancer AND MTOR, FRAP2, FRAP1, 2475, ENSG00000198793, P42345, RAPT1, RAFT1, FRAP, FLJ44809 AND Clinical Outcome
11 results:
1. Imatinib revives the therapeutic potential of metformin on ewing sarcoma by attenuating tumor hypoxic response and inhibiting convergent signaling pathways.
Nan X; Wang J; Cheng H; Yin Z; Sheng J; Qiu B; Lau CC; Yustein JT; Zhao H; Wong STC
Cancer Lett; 2020 Jan; 469():195-206. PubMed ID: 31672491
[TBL] [Abstract] [Full Text] [Related]
2. ALDH1A1-related stemness in high-grade serous ovarian cancer is a negative prognostic indicator but potentially targetable by EGFR/mtor-PI3K/aurora kinase inhibitors.
Kaipio K; Chen P; Roering P; Huhtinen K; Mikkonen P; Östling P; Lehtinen L; Mansuri N; Korpela T; Potdar S; Hynninen J; Auranen A; Grénman S; Wennerberg K; Hautaniemi S; Carpén O
J Pathol; 2020 Feb; 250(2):159-169. PubMed ID: 31595974
[TBL] [Abstract] [Full Text] [Related]
3. Genomic Features of Metastatic Testicular Sex Cord Stromal Tumors.
Necchi A; Bratslavsky G; Shapiro O; Elvin JA; Vergilio JA; Killian JK; Ngo N; Ramkissoon S; Severson E; Hemmerich AC; Ali SM; Chung JH; Reddy P; Miller VA; Schrock AB; Gay LM; Ross JS; Jacob JM
Eur Urol Focus; 2019 Sep; 5(5):748-755. PubMed ID: 31147264
[TBL] [Abstract] [Full Text] [Related]
4. The mtor downstream regulator (p-4EBP1) is a novel independent prognostic marker in ovarian cancer.
Alabdullah ML; Ahmad DA; Moseley P; Madhusudan S; Chan S; Rakha E
J Obstet Gynaecol; 2019 May; 39(4):522-528. PubMed ID: 30712414
[TBL] [Abstract] [Full Text] [Related]
5. clinical outcome of treatment with serine-threonine kinase inhibitors in recurrent epithelial ovarian cancer: a systematic review of literature.
Ciccone MA; Maoz A; Casabar JK; Machida H; Mabuchi S; Matsuo K
Expert Opin Investig Drugs; 2016 Jul; 25(7):781-96. PubMed ID: 27101098
[TBL] [Abstract] [Full Text] [Related]
6. Enhanced GAB2 Expression Is Associated with Improved Survival in High-Grade Serous ovarian cancer and Sensitivity to PI3K Inhibition.
Davis SJ; Sheppard KE; Anglesio MS; George J; Traficante N; Fereday S; Intermaggio MP; Menon U; Gentry-Maharaj A; Lubinski J; Gronwald J; Pearce CL; Pike MC; Wu A; Kommoss S; Pfisterer J; du Bois A; Hilpert F; Ramus SJ; Bowtell DD; Huntsman DG; Pearson RB; Simpson KJ; Campbell IG; Gorringe KL
Mol Cancer Ther; 2015 Jun; 14(6):1495-503. PubMed ID: 25852062
[TBL] [Abstract] [Full Text] [Related]
7. CD157 enhances malignant pleural mesothelioma aggressiveness and predicts poor clinical outcome.
Ortolan E; Giacomino A; Martinetto F; Morone S; Lo Buono N; Ferrero E; Scagliotti G; Novello S; Orecchia S; Ruffini E; Rapa I; Righi L; Volante M; Funaro A
Oncotarget; 2014 Aug; 5(15):6191-205. PubMed ID: 25026285
[TBL] [Abstract] [Full Text] [Related]
8. Temsirolimus and pegylated liposomal doxorubicin (PLD) combination therapy in breast, endometrial, and ovarian cancer: phase Ib results and prediction of clinical outcome with FDG-PET/CT.
Boers-Sonderen MJ; de Geus-Oei LF; Desar IM; van der Graaf WT; Oyen WJ; Ottevanger PB; van Herpen CM
Target Oncol; 2014 Dec; 9(4):339-47. PubMed ID: 24577626
[TBL] [Abstract] [Full Text] [Related]
9. Targeted cancer therapy--are the days of systemic chemotherapy numbered?
Joo WD; Visintin I; Mor G
Maturitas; 2013 Dec; 76(4):308-14. PubMed ID: 24128673
[TBL] [Abstract] [Full Text] [Related]
10. Promoter CpG island methylation of genes in key cancer pathways associates with clinical outcome in high-grade serous ovarian cancer.
Dai W; Zeller C; Masrour N; Siddiqui N; Paul J; Brown R
Clin Cancer Res; 2013 Oct; 19(20):5788-5797. PubMed ID: 23965899
[TBL] [Abstract] [Full Text] [Related]
11. Tissue and serum biomarkers as prognostic variables in endometrioid-type endometrial cancer.
Gadducci A; Cosio S; Genazzani AR
Crit Rev Oncol Hematol; 2011 Nov; 80(2):181-92. PubMed ID: 21134766
[TBL] [Abstract] [Full Text] [Related]